ZA200101614B - Inhibition of graft versus host disease. - Google Patents
Inhibition of graft versus host disease. Download PDFInfo
- Publication number
- ZA200101614B ZA200101614B ZA200101614A ZA200101614A ZA200101614B ZA 200101614 B ZA200101614 B ZA 200101614B ZA 200101614 A ZA200101614 A ZA 200101614A ZA 200101614 A ZA200101614 A ZA 200101614A ZA 200101614 B ZA200101614 B ZA 200101614B
- Authority
- ZA
- South Africa
- Prior art keywords
- cells
- oxidative stress
- cell
- population
- ozone
- Prior art date
Links
- 208000009329 Graft vs Host Disease Diseases 0.000 title claims description 30
- 208000024908 graft versus host disease Diseases 0.000 title claims description 30
- 230000005764 inhibitory process Effects 0.000 title description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 73
- 238000000034 method Methods 0.000 claims description 54
- 210000004027 cell Anatomy 0.000 claims description 53
- 230000008569 process Effects 0.000 claims description 37
- 230000036542 oxidative stress Effects 0.000 claims description 30
- 210000000130 stem cell Anatomy 0.000 claims description 26
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 23
- 230000000735 allogeneic effect Effects 0.000 claims description 20
- 230000005855 radiation Effects 0.000 claims description 20
- 239000000725 suspension Substances 0.000 claims description 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
- 239000007800 oxidant agent Substances 0.000 claims description 12
- 239000001301 oxygen Substances 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 239000007789 gas Substances 0.000 claims description 11
- 230000016396 cytokine production Effects 0.000 claims description 10
- 230000009696 proliferative response Effects 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 8
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 7
- 229910001882 dioxygen Inorganic materials 0.000 claims description 7
- 230000003247 decreasing effect Effects 0.000 claims description 6
- 230000002757 inflammatory effect Effects 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 238000010322 bone marrow transplantation Methods 0.000 claims description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 208000015322 bone marrow disease Diseases 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims description 3
- 239000008246 gaseous mixture Substances 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 239000007900 aqueous suspension Substances 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000005087 mononuclear cell Anatomy 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 10
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 10
- 210000001185 bone marrow Anatomy 0.000 description 10
- 239000003102 growth factor Substances 0.000 description 10
- 230000004044 response Effects 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 210000004989 spleen cell Anatomy 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 239000012894 fetal calf serum Substances 0.000 description 6
- 230000001590 oxidative effect Effects 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 3
- 238000011579 SCID mouse model Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000005587 bubbling Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000002939 deleterious effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical class OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- 241001415166 Alona Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000015215 Stem Cell Factor Human genes 0.000 description 1
- 108010039445 Stem Cell Factor Proteins 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011368 intensive chemotherapy Methods 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000000329 lymphopenic effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005316 response function Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
- A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2244554 CA2244554A1 (en) | 1998-07-30 | 1998-07-30 | Inhibition of graft versus host disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200101614B true ZA200101614B (en) | 2002-01-02 |
Family
ID=4162727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200101614A ZA200101614B (en) | 1998-07-30 | 2001-02-27 | Inhibition of graft versus host disease. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6258357B1 (zh) |
| EP (1) | EP1100875A2 (zh) |
| JP (1) | JP2002523332A (zh) |
| KR (1) | KR20010072095A (zh) |
| CN (1) | CN1314939A (zh) |
| AU (1) | AU755630B2 (zh) |
| BR (1) | BR9912594A (zh) |
| CA (1) | CA2244554A1 (zh) |
| CZ (1) | CZ2001316A3 (zh) |
| EA (1) | EA200100195A1 (zh) |
| IL (1) | IL141007A0 (zh) |
| MX (1) | MXPA01001144A (zh) |
| NO (1) | NO20010490L (zh) |
| NZ (1) | NZ509387A (zh) |
| WO (1) | WO2000006703A2 (zh) |
| ZA (1) | ZA200101614B (zh) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE516133C2 (sv) * | 1999-02-25 | 2001-11-19 | Lundblad Leif J I | Användning av vissa substituerade indolokinoxaliner för framställning av ett medel för skydd av vävnader, organ och celler vid transplantation |
| US8147824B2 (en) * | 1999-08-05 | 2012-04-03 | Athersys, Inc. | Immunomodulatory properties of multipotent adult progenitor cells and uses thereof |
| CA2324199A1 (en) | 2000-10-25 | 2002-04-25 | Vasogen Ireland Limited | Chronic lymphocytic leukemia treatment |
| ATE538785T1 (de) * | 2001-07-31 | 2012-01-15 | Genzyme Global S A R L | Verfahren zur mobilisierung von vorläufer/stammzellen |
| US7037900B2 (en) * | 2001-10-12 | 2006-05-02 | Supergen, Inc. | Composition and method for treating graft-versus-host disease |
| CA2490401A1 (en) * | 2002-06-28 | 2004-01-08 | Xcyte Therapies, Inc. | Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| US20040175373A1 (en) * | 2002-06-28 | 2004-09-09 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| US20050084967A1 (en) * | 2002-06-28 | 2005-04-21 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| US7189694B2 (en) * | 2003-04-18 | 2007-03-13 | University Of Florida Research Foundation, Inc. | Inhibitors of autophosphorylation protein kinases |
| WO2007011960A2 (en) * | 2005-07-18 | 2007-01-25 | Advanced Immune Biotechnologies, Inc. | Methods and agents to treat autoimmune diseases |
| US20100196327A1 (en) * | 2007-04-11 | 2010-08-05 | Cell Science Systems | Methods for diagnosing biological samples containing stem cells |
| AU2008331501B2 (en) * | 2007-11-30 | 2014-09-04 | New York Medical College | Methods of isolating non-senescent cardiac stem cells and uses thereof |
| US8512696B2 (en) * | 2007-11-30 | 2013-08-20 | Autologous, Llc | Methods of isolating non-senescent cardiac stem cells and uses thereof |
| EP3219793A1 (en) * | 2012-01-05 | 2017-09-20 | Taipei Veterans General Hospital | Preparation of cell transplant |
| RU2508924C1 (ru) * | 2013-02-21 | 2014-03-10 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" | Способ профилактики и лечения отторжения почечного трансплантата |
| JP7445946B2 (ja) * | 2019-06-12 | 2024-03-08 | 国立大学法人九州大学 | 性質変化方法及びプラズマ生成装置 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5980954A (en) * | 1992-02-07 | 1999-11-09 | Vasogen Ireland Limited | Treatment of autoimmune diseases |
| CA2220971A1 (en) * | 1995-05-25 | 1996-11-28 | Baxter International Inc. | Allogeneic cell therapy for cancer following allogeneic stem cell transplantation |
| EP0797967B1 (en) * | 1996-03-29 | 2000-08-23 | The Procter & Gamble Company | Method for assessing disposable absorbent structures |
-
1998
- 1998-07-30 CA CA 2244554 patent/CA2244554A1/en not_active Abandoned
-
1999
- 1999-07-30 EA EA200100195A patent/EA200100195A1/ru unknown
- 1999-07-30 NZ NZ50938799A patent/NZ509387A/xx unknown
- 1999-07-30 JP JP2000562485A patent/JP2002523332A/ja active Pending
- 1999-07-30 BR BR9912594A patent/BR9912594A/pt not_active IP Right Cessation
- 1999-07-30 MX MXPA01001144A patent/MXPA01001144A/es unknown
- 1999-07-30 US US09/363,678 patent/US6258357B1/en not_active Expired - Fee Related
- 1999-07-30 IL IL14100799A patent/IL141007A0/xx unknown
- 1999-07-30 CN CN99810240A patent/CN1314939A/zh active Pending
- 1999-07-30 EP EP19990936202 patent/EP1100875A2/en not_active Withdrawn
- 1999-07-30 CZ CZ2001316A patent/CZ2001316A3/cs unknown
- 1999-07-30 AU AU51433/99A patent/AU755630B2/en not_active Ceased
- 1999-07-30 WO PCT/CA1999/000706 patent/WO2000006703A2/en active Search and Examination
- 1999-07-30 KR KR1020017001235A patent/KR20010072095A/ko not_active Application Discontinuation
-
2001
- 2001-01-29 NO NO20010490A patent/NO20010490L/no not_active Application Discontinuation
- 2001-02-27 ZA ZA200101614A patent/ZA200101614B/en unknown
- 2001-05-14 US US09/853,755 patent/US20010028879A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2244554A1 (en) | 2000-01-30 |
| MXPA01001144A (es) | 2002-04-24 |
| EA200100195A1 (ru) | 2001-10-22 |
| EP1100875A2 (en) | 2001-05-23 |
| NO20010490L (no) | 2001-03-29 |
| CN1314939A (zh) | 2001-09-26 |
| NO20010490D0 (no) | 2001-01-29 |
| JP2002523332A (ja) | 2002-07-30 |
| AU755630B2 (en) | 2002-12-19 |
| CZ2001316A3 (cs) | 2001-10-17 |
| WO2000006703A2 (en) | 2000-02-10 |
| BR9912594A (pt) | 2002-04-23 |
| KR20010072095A (ko) | 2001-07-31 |
| WO2000006703A3 (en) | 2000-05-04 |
| US20010028879A1 (en) | 2001-10-11 |
| US6258357B1 (en) | 2001-07-10 |
| AU5143399A (en) | 2000-02-21 |
| NZ509387A (en) | 2002-10-25 |
| IL141007A0 (en) | 2002-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6258357B1 (en) | Inhibition of graft versus host disease | |
| Korbelik et al. | Photodynamic therapy-mediated immune response against subcutaneous mouse tumors | |
| DE60201783T2 (de) | Pharmazeutische Zusammensetzung enthaltend nicht-MHC-abhängige T-Zellen/NK-Zellen und MHC-abhängige Zellen zur Behandlung von Tumoren | |
| Sykes et al. | Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4-and CD8-mediated graft-versus-leukemia effects | |
| Andreu et al. | The role of UV radiation in the prevention of human leukocyte antigen alloimmunization | |
| US5571082A (en) | Method of producing therapeutic effect upon an organism to reduce the pathologic lymphocyte population | |
| Melder et al. | Systemic distribution and tumor localization of adoptively transferred lymphocytes in mice: comparison with physiologically based pharmacokinetic model | |
| US20030108536A1 (en) | Inhibition of graft versus host disease | |
| CA2356882A1 (en) | Graft versus host disease | |
| Sasaki et al. | Transplantation of allogeneic peripheral blood stem cells after myeloablative treatment of a patient in blastic crisis of chronic myelocytic leukemia | |
| Chowdhury et al. | Donor-specific unresponsiveness to murine cardiac allografts induced by intrathymic-soluble alloantigens is dependent on alternate pathway of antigen presentation | |
| Johnson et al. | Sca1+/Mac1+ Nitric Oxide-Producing Cells in the Spleens of Recipients Early Following Bone Marrow Transplant Suppress T Cell Responsesin Vitro | |
| CA2398401A1 (en) | Improved inhibition of graft versus host disease | |
| Rosenfeld et al. | Ex vivo purging of allogeneic marrow with L-leucyl-L-leucine methyl ester: a phase I study | |
| Wängberg et al. | Accumulation of natural killer cells after hepatic artery embolisation in the midgut carcinoid syndrome | |
| US20030157114A1 (en) | Treatment of autoimmune diseases | |
| Sheng-Tanner et al. | Characterization of graft-versus-host disease in SCID mice and prevention by physicochemical stressors | |
| Black et al. | Immunobiology of lipid-modulated UV-carcinogenesis | |
| Uchida et al. | Combination Treatment with Irritant and Recombinant Interleukin 2 in the Peritoneal Cavity for Evoking Effective Anti‐tumor Activity: Generation of Lymphokine‐activated Killer Cells and Tumor‐specific Killer Cells | |
| Herberman | Therapy of cancer with interleukin-2-activated natural killer cells | |
| TAMURA et al. | Augmentation of delayed-type hypersensitivity and resistance against allogeneic or syngeneic methylcholanthrene-induced tumors in mice preimmunized with the tumor extracts | |
| Collins et al. | Characterization of a low molecular weight suppressor of lymphocyte proliferation from guinea pig 12C leukemia cells | |
| Gold et al. | Autolymphocyte Therapy: III. Effective Adjuvant Adoptive Cellular Therapy with in Vivo Anti-tumor Specificity against Murine Melanoma and Carcinoma Using ex-Vivo-Activated Memory T-Lymphocytes | |
| Lefor et al. | Lymphokine-activated killer cells: biology and therapeutic efficacy | |
| Kan et al. | In vivo and in vitro synergistic antitumor effect of interleukin-2-cultured tumor-bearer spleen cells and immune fresh spleen cells |